Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Director | June 01, 2026 | June 03, 2026 |
| DBV Technologies S.A.DBVT · Entity 5096 | Director | June 10, 2021 | June 11, 2021 |
| Pharvaris N.V.PHVS · Entity 4374 | Director | September 23, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 186,447 |
Ending reported balance
After 2026-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-01 · Grant · Acquired 45,000 · Balance 189,043 F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-03 · Tax withholding · Disposed 2,596 · Balance 186,447 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.
DBV Technologies S.A.
Report date June 10, 2021 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.09 · Expires 2025-06-10 | Direct | 5,000 |
Reported balance
After 2021-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-10 · Purchase · Acquired 5,000 · Balance 5,000 F1: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.
Pharvaris N.V.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,500 |
Ending reported balance
After 2026-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-23 · Exercise / conversion · Acquired 11,969 · Balance 17,469 Row 2 · 2026-09-23 · Sale · Disposed 11,969 · Balance 5,500 F1: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $33.00 to $33.0801. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2033-04-06 | Direct | 9,031 |
Reported balance
After 2026-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-23 · Exercise / conversion · Disposed 11,969 · Balance 9,031 F2: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $33.00 to $33.0801. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F2: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 17:35 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,969 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001193125-26-402567 · ownership.xml · derivative · entry 3 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,031 Underlying: Common Stock · 11,969 shares Expires 2033-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 17:35 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 11,969 | $33.05 | $395,523.98 |
DisclosureSEC source: 0001193125-26-402567 · ownership.xml · nonDerivative · entry 2 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $33.00 to $33.0801. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 17:35 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 11,969 | $8.05 | $96,350.45 |
DisclosureSEC source: 0001193125-26-402567 · ownership.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 21:03 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 2,596 | $3.08 | $7,995.68 |
DisclosureSEC source: 0001628280-26-040490 · wk-form4_1780520578.xml · nonDerivative · entry 2 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,447 F2 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:03 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040490 · wk-form4_1780520578.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,043 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 21, 2026 Filed May 26, 2026 21:53 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 9,667 | $30.29 | $292,853.06 |
DisclosureSEC source: 0001193125-26-239754 · ownership.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 F1 · shares: The total number of shares beneficially owned previously reported in the Form 3 filed on March 18, 2026 was understated by 513 shares due to administrative errors in the number of shares reported as withheld for tax obligations in connection with RSU releases occurring on April 11, 2025 and March 12, 2026. This filing reflects the corrected beneficial ownership amount. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $30.08 to $30.49 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:02 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 2,584 | $3.58 | $9,250.72 |
DisclosureSEC source: 0001628280-25-031893 · wk-form4_1750194163.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,043 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:07 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029729 · wk-form4_1749157579.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,627 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:40 UTC | ADC Therapeutics SA ADCT · Entity 6502 | SaleCommon Shares | 1,437 | $2.89 | $4,152.93 |
DisclosureSEC source: 0001628280-24-028990 · wk-form4_1718761205.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,627 F1 · kind: Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:23 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-028339 · wk-form4_1718400187.xml · nonDerivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,064 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:52 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseWarrant (right to buy) · Derivative | 5,000 | $7.12 Strike: $13.09 | $35,600.00 |
DisclosureSEC source: 0001209191-21-039884 · doc4.xml · derivative · entry 1 Monges Viviane · CIK 0001838204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires 2025-06-10 F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.